Holen Sie sich die Stockscreener-App
73.65
0.54%
-0.40
Handel nachbörslich:
73.65
Spyre Therapeutics Inc Aktie (SYRE) Neueste Nachrichten
SYRE Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
SYRE Technical Analysis | Trend, Signals & Chart Patterns | SPYRE THERAPEUTICS INC (NASDAQ:SYRE) - ChartMill
Spyre Therapeutics, Inc. advances new therapies for ulcerative colitis and Crohns disease - Traders Union
JonesTrading Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $95 - Moomoo
LifeSci Capital Sticks to Its Buy Rating for Spyre Therapeutics (SYRE) - The Globe and Mail
Spyre Therapeutics (SYRE) price target increased by 42.03% to 88.06 - MSN
SYRE stock jumps more than 70% in a month: What is driving this rally? - MSN
TradingKey - TradingKey
Deutsche Bank Adjusts Spyre Therapeutics Price Target to $102 From $86, Maintains Buy Rating - Moomoo
Deutsche Bank Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $102 - Moomoo
Stifel Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $107 - Moomoo
UBS Group AG Has $22.30 Million Stake in Spyre Therapeutics, Inc. $SYRE - MarketBeat
Spyre Therapeutics stock hits 52-week high at $76.56 By Investing.com - Investing.com India
Hot Picks: Biotech stocks gain on cancer drugs and trial data - BNN Bloomberg
Spyre Therapeutics stock hits 52-week high at $76.56 - Investing.com
Spyre Therapeutics Insider Sold Shares Worth $5,952,050, According to a Recent SEC Filing - marketscreener.com
Spyre Therapeutics (SYRE) Receives a Rating Update from a Top Analyst - The Globe and Mail
F m Investments LLC Acquires 48,825 Shares of Spyre Therapeutics, Inc. $SYRE - MarketBeat
LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $103 - Moomoo
Spyre Therapeutics director Michael Henderson sells $5.95 million in shares - Investing.com India
Insider Sell Alert: Michael Henderson Sells 80,000 Shares of Spy - GuruFocus
Spyre Therapeutics director Michael Henderson sells $5.95 million in shares By Investing.com - Investing.com South Africa
Spyre Therapeutics (SYRE) director sells 80,000 shares in planned trades - Stock Titan
Spyre Therapeutics(SYRE.US) Director Sells US$5.95 Million in Common Stock - Moomoo
[144] Spyre Therapeutics, Inc. SEC Filing - Stock Titan
Spyre Therapeutics | SCHEDULE 13G: Others - Moomoo
Citi Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $97 - Moomoo
Stifel Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $107 - Moomoo
Analysts Conflicted on These Healthcare Names: Pfizer (PFE), Spyre Therapeutics (SYRE) and Adaptive Biotechnologies (ADPT) - The Globe and Mail
Spyre Therapeutics flies on Takeda-rivaling ulcerative colitis results - MSN
Spyre Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
A Quick Look at Today's Ratings for Spyre Therapeutics(SYRE.US), With a Forecast Between $97 to $107 - Moomoo
Jefferies Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $95 - Moomoo
Spyre Therapeutics’ Exclusive Forum Clauses Shift Legal Leverage, Raise Venue and Litigation Cost Concerns for Stockholders - TipRanks
Stifel raises Spyre stock price target to $107 on UC data strength - Investing.com
MSN Money - MSN
Spyre Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Spyre Therapeutics | 10-Q: Q1 2026 Earnings Report - Moomoo
Spyre Therapeutics Q1 Loss Widens - Moomoo
Earnings Flash (SYRE) Spyre Therapeutics Posts Q1 Net Loss $0.74 a Share, vs. FactSet Est of $0.67 Loss - marketscreener.com
Spyre Therapeutics, Inc. Q1 operating expenses USD 45.641 million - marketscreener.com
According to the latest financial data from biopharmaceutical company Spyre Therapeutics Inc, as of March 31, 2026, the company's total cash, cash equivalents, and marketable securities amounted to 741.5 millions USD. - bitget.com
Biotech Spyre lines up six 2026 trial readouts with $1.2B cash - Stock Titan
Spyre Therapeutics, Inc. 1Q 2026: Net loss $(69.0)M, EPS $(0.74) — 10-Q Summary - TradingView
Earnings Flash (SYRE) Spyre Therapeutics Posts Q1 Net Loss $0.74 a Share, Vs. FactSet Est of $0.67 Loss - Moomoo
Spyre Therapeutics posts wider-than-expected Q1 net loss - TradingView
Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Spyre Therapeutics: Q1 Earnings Snapshot - Barchart.com
SYRE: Strong clinical progress and robust cash position support long-term growth despite higher net loss - TradingView
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):